Comment on

• The effect of low molecular weight heparin on survival in patients with advanced malignancy.

  Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Büller HR. Klerk CP, et al. J Clin Oncol. 2005 Apr 1;23(10):2130-5. doi: 10.1200/JCO.2005.03.134. Epub 2005 Feb 7. J Clin Oncol. 2005. PMID: 15699479 Clinical Trial.
• Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.

  Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Lee AY, et al. J Clin Oncol. 2005 Apr 1;23(10):2123-9. doi: 10.1200/JCO.2005.03.133. Epub 2005 Feb 7. J Clin Oncol. 2005. PMID: 15699480 Clinical Trial.